PLAT and Sepsis: In Group C, patients were deemed ineligible for idarucizumab due to the reasons such as receiving intra-arterial thrombectomy (IA) or tissue plasminogen activator (TPA) infusion (45.5%, n = 5), not taking dabigatran (36.4%, n = 4), sepsis with disseminated intravascular coagulation but without active bleeding (9.1%, n = 1), and minor intramuscular bleeding (9.1%, n = 1).